Actively Recruiting
Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Advanced Squamous NSCLC Patients: A Retrospective Real-World Study Based on RATIONALE-307
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-03-27
109
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to collect long-term survival data from patients with advanced squamous non-small cell lung cancer (NSCLC) who received first-line treatment with tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to gather more evidence on the long-term benefits of immunotherapy for these patients and to identify those who may gain greater clinical advantage from this treatment approach. The study is observational and involves no new interventions. It focuses on patients who participated in the RATIONALE-307 trial and were alive at the completion of that study. There are no additional treatments or experimental procedures in this follow-up period. Participants will have their overall survival data collected retrospectively, defined as the time from randomization in the RATIONALE-307 trial until death from any cause occurring on or before December 31, 2025. The study will analyze this data to better understand long-term outcomes. Since this is a retrospective study, there is no active involvement or new assessments required from participants beyond data collection.
CONDITIONS
Brief Title
A Retrospective Real-World Study Based on RATIONALE-307
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial
- Patients who had no documented death before study completion
You will not qualify if you...
- Patients who had a documented death before study completion in the RATIONALE-307 trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
/null
Duration - Up to December 31, 2025
Participants who previously received treatment in the RATIONALE-307 trial are observed for overall survival and safety outcomes over time.
/null
Trial Site Locations
Total: 1 location
1
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Actively Recruiting
Research Team
Z
Zhijie Wang, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here